Keywords: AstraZeneca, Brilique, Brilinta, UK, NICE, Blood thinner, PTC Thera, GEMS technology, Cancer research

AstraZeneca gets UK NICE backing for Brilique; collaborates with PTC for oncology and other potential drugs

Article | 30 June 2011

Print This

There was good news this morning for Anglo-Swedish drug major AstraZeneca (LSE: AZN), when the UK’s drug watchdog, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in